ZTS · Zoetis Inc.
$73.79
-2.05 (-2.70%)
At close · Aug 14
Market Cap
$30.49B
Shares
413.22M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Juan Ramón Alaix | Chief Executive Officer | $21,145,419 |
| Glenn David | Executive Vice President and Chief Financial Officer | $3,672,350 |
| Clinton A. Lewis | Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human | $3,556,353 |
| Kristin Peck | Executive Vice President and Group President, U.S. Operations, Business Development and Strategy | $3,330,164 |
| Catherine A. Knupp | Executive Vice President and President of Research and Development | $3,311,222 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Juan Ramón Alaix | Chief Executive Officer | $11,669,400 |
| Clinton A. Lewis | Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human | $4,625,806 |
| Kristin Peck | Executive Vice President and Group President, U.S. Operations, Business Development and Strategy | $3,038,924 |
| Glenn David | Executive Vice President and Chief Financial Officer | $3,035,171 |
| Catherine A. Knupp | Executive Vice President and President of Research and Development | $2,923,941 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Juan Ramón Alaix | Chief Executive Officer | $10,528,769 |
| Clinton A. Lewis | Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human | $4,447,246 |
| Kristin Peck | Executive Vice President and Group President, U.S. Operations, Business Development and Strategy | $3,066,603 |
| Catherine A. Knupp | Executive Vice President and President of Research and Development | $2,916,558 |
| Glenn David | Executive Vice President and Chief Financial Officer | $2,797,597 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James Saccaro | Executive Vice President, Chief Financial Officer and Chief Operating Officer | Appointed | 2026-08-06 |
| James Saccaro | Executive Vice President, Chief Financial Officer and Chief Operating Officer | Appointed | 2026-08-06 |
| Louise M. Parent | Board of Directors | Retired | 2026-05-22 |
| Stephanie Tilenius | Board of Directors | Appointed | 2025-10-28 |
| Mark Stetter | Board of Directors | Appointed | 2025-05-22 |
| Robert Scully | Board of Directors | Retired | 2025-05-22 |
| Heidi C. Chen | Executive Vice President, General Counsel and Corporate Secretary; Business Lead of Human Health Diagnostics | Terminated | 2024-05-24 |
| Dr. Linda Rhodes | Board of Directors | Retired | 2024-05-23 |
| Roxanne Lagano | interim General Counsel and Corporate Secretary | Appointed | 2024-04-16 |
| Gavin D.K. Hattersley | Board of Directors | Appointed | 2024-04-01 |
| Glenn David | Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices | Terminated | 2023-02-07 |
| Jamie Brannan | Executive Vice President and Group President, International Operations and Aquaculture (PHARMAQ) | Appointed | 2022-10-25 |
| Glenn David | Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices | Appointed | 2022-10-25 |
| Vanessa Broadhurst | member of the Board | Appointed | 2022-07-25 |
| Roman Trawicki | Executive Vice President and President, Global Manufacturing and Supply | Retired | 2022-04-21 |
Key facts
CIK
1555280
CUSIP
98978V103
13F (30d)
1256 filings
1206 filers
Visit website
Investor relations